FDA grants IND Approval for Stemedica's itMSC Therapy for COVID-19 Patients

▴ FDA grants IND Approval for Stemedica's itMSC Therapy for COVID-19 Patients
The study will enrol up to 40 patients into two cohorts, randomized 1:1 to receive the active study drug plus standard treatment or placebo

Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for "A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients with Moderate to Severe Lung Injury due to COVID-19." The study will enrol up to 40 patients into two cohorts, randomized 1:1 to receive the active study drug plus standard treatment or placebo (lactate ringer solution) plus standard treatment.

Prior to submission of an IND, fourteen critically ill COVID-19 patients were treated on Emergency Use and Expanded Use INDs at the Providence Saint John's Health Center (Santa Monica, CA) and ProMedica (Toledo, OH). The stem cell treatment resulted in an improved clinical course for the patients. Within 24-48 hours of receiving the stem cells, all patients had a significant reduction in oxygen requirements. Several patients went from an inability to talk or eat due to shortness of breath to speaking in full sentences and eating full meals comfortably shortly after treatment.

The study also found improved inflammatory modulation; 88 percent of patients had a significant reduction in acute phase reactants (markers for reductions in inflammation) which resulted in a reduced "cytokine storm." Researchers noted that these patients experienced quicker extubation, less lung trauma and less oxygen toxicity.

"It was evident from this preliminary experience that ischemic-tolerant mesenchymal stem cells (itMSCs) may play a significant role in treating moderate and severe cases of COVID-19 and require further investigation in a clinical trial to be sponsored by Stemedica," said Lev Verkh Ph.D., Stemedica's chief regulatory and clinical development officer.

Several properties of itMSCs make them attractive as a novel biological therapy for severe lung injury due to COVID-19: low immunogenicity; immunomodulatory effects; capacity to suppress excessive pro-inflammatory responses; and ability to secrete epithelial and endothelial growth factors to support the existing alveolar epithelial and endothelial barriers which are often disrupted in acute respiratory distress syndrome (ARDS) leading to respiratory failure from alveolar edema. By targeting multiple aspects of the pathophysiology of ARDS, itMSCs offer a distinct advantage over other pharmacological therapies that may target one component of the syndrome.

"Mesenchymal stem cells that act as a cytokine storm blocker significantly suppress natural killer (NK) cell activation, reducing CXCL1 peptides released by neutrophils resulting in a lesser presence harmful to the epithelium and endothelium proteases and oxidants," said Nikolai Tankovich M.D., Ph.D., Stemedica's president and chief medical officer. "This results in less damage to the lungs and a better clinical outcome for COVID-19 patients, in particular, for breathing capability."

Tags : #StemedicasItmscTherapy #Stemedicas #FDAApproval #LatestPharmaNewsUpdateSep29 #LatestFdaApprovalNewsSep29

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024